Antilfa (odulimomab) / Sanofi - LARVOL DELTA

C-Met: a new signature of pro-inflammatory CD4+ T cells in multiple sclerosis (ECTRIMS 2025) - "These results emphasize c-Met as an immune marker of highly pro-inflammatory and pro-migratory CD4+ T lymphocytes in MS."

CNS Disorders • Multiple Sclerosis • CD4 • IFNG • IL17A • ITGA4 • ITGB1 • MET • NTRK3

Pro-Inflammatory c-Met+ CD4 T Cells in Multiple Sclerosis. (PubMed, Ann Neurol) - "These results emphasize c-Met as an immune marker of highly pro-inflammatory and migratory CD4 T lymphocytes in both the periphery and central nervous system of MS patients. ANN NEUROL 2025."

Journal • CNS Disorders • Immunology • Multiple Sclerosis • CD4 • IL17A • ITGA4 • MET

Comparative Efficacy and Safety of Induction Therapy in Solid Organ Transplantation: A Systematic Review and Network Meta-Analysis (WTC 2025) - "Ranking probabilities based on the surface under the cumulative ranking curve (SUCRA) indicated that alemtuzumab (SUCRA 93.9%) exhibited the highest potential superiority in reducing the rejection rate, followed by ALG, belimumab, rATG, OKT3, daclizumab, odulimomab, basiliximab, rituximab, Lo-tact-1, and inolimomab... Alemtuzumab is the most effective therapy for reducing the rejection rate. OKT3 is the primary therapeutic option for enhancing graft survival. Basiliximab is an important therapeutic option for improving overall survival."

Retrospective data • Review • Infectious Disease • Solid Organ Transplantation • Transplantation

c-Met: A New Signature of Pro-inflammatory CD4+ T Cells in Multiple Sclerosis (AAN 2025) - "These results emphasize c-Met as an immune marker of highly pro-inflammatory and pro-migratory CD4+ T lymphocytes in MS."

CNS Disorders • Multiple Sclerosis • CD4 • IFNG • IL17A • ITGA4 • ITGB1 • MET • NTRK3